6 months ago • 2 mins
What’s going on here?
AstraZeneca, the UK’s pharmaceutical titan, is reportedly shooting for the stars with a new Chinese gambit.
What does this mean?
According to the Financial Times, AstraZeneca is drafting some big new plans: spinning off its Chinese business and listing it separately on the Hong Kong or Shanghai stock exchange. The game plan here is to keep control of the business – which brought in 13% of AstraZeneca’s total revenue last year – while making it a neat-and-tidy separate entity. And that could be a pretty wily move: first, it offers AstraZeneca a separate treasure chest of capital to fund growth in China – a populous, aging, and increasingly lucrative market for pharmaceutical companies. Second, a Chinese listing could help AstraZeneca win faster approvals for drugs developed in the country. And last but not least, it could provide AstraZeneca’s China business with a handy shield from the world’s increasingly messy geopolitical squalls too.
Why should I care?
The bigger picture: Pivots and politics.
That third reason is arguably the biggest one – and it hints at a possible sea change for multinationals, as friction between China and the West mounts. And word on the street is that every multinational with a footprint in China is contemplating a similar move. That’s not just boardroom gossip: venture capital powerhouse Sequoia Capital, for one, recently announced that it’s going to split in three, separating its Chinese and US operations as tensions grow between the world’s two biggest economies.
For markets: Tokyo drift.
Japanese stocks might just find themselves in the spotlight as this drama unfolds. See, California-based wealth management firm Bailar thinks that the Land of the Rising Sun could bask in the glow of a trend they’ve dubbed “friend-shoring”. In other words, as tensions rise with China, European and US companies just might shift their trade reliance to Japan, turf that’s currently free of any nasty geopolitical storms.
Disclaimer: These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment advisor.
/3 • Your free quarterly content is about to expire. Uncover the biggest trends and opportunities. Subscribe now for 50%. Cancel anytime.